Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer's disease

Molecular Neurodegeneration

Volumn 9, Issue 1, 2014, Pages

  Landel, Véréna ^a   Baranger, Kévin ^a,b   Virard, Isabelle ^a   Loriod, Béatrice ^c   Khrestchatisky, Michel ^a   Rivera, Santiago ^a   Benech, Philippe ^a   Féron, François ^a  

^a Mediterranée University   (France)

^b TIMONE HOSPITAL   (France)

^c Aix Marseille university   (France)

Author keywords

GTPase signaling; Hippocampus; Inflammation; Interferon; Microglia; Neocortex; Neuro immune processes; Oxidative stress; Phagocytosis; Transcriptome

Indexed keywords

COMPLEMENT; GAMMA INTERFERON; INTEGRIN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSCRIPTOME;

5XFAD MOUSE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; IMMUNITY; INFLAMMATION; LONGITUDINAL STUDY; MICROGLIA; MOUSE; NEOCORTEX; NONHUMAN; PHAGOCYTOSIS; RNA ANALYSIS; ANIMAL; BRAIN; DISEASE MODEL; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, TRANSGENIC; MICROGLIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84907173621     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-9-33     Document Type: Article

References (166)

1. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R, J Neurosci 2006 26 10129 10140
2. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Hardy J, Selkoe DJ, Science 2002 297 353 356
3. Dynamic analysis of amyloid beta-protein in behaving mice reveals opposing changes in ISF versus parenchymal Abeta during age-related plaque formation. Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ, J Neurosci 2011 31 15861 15869
4. Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. Masters CL, Selkoe DJ, Cold Spring Harb Perspect Biol Med 2012 2 006262
5. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Mucke L, Selkoe DJ, Cold Spring Harb Perspect Biol Med 2012 2 006338
6. Systematic evaluation of candidate ligands regulating ectodomain shedding of amyloid precursor protein. Rice HC, Young-Pearse TL, Selkoe DJ, Biochemistry 2013 52 3264 3277
7. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Kimura R, Ohno M, Neurobiol Dis 2009 33 229 235
8. Area-specific alterations of synaptic plasticity in the 5XFAD mouse model of Alzheimer's disease: dissociation between somatosensory cortex and hippocampus. Crouzin N, Baranger K, Cavalier M, Marchalant Y, Cohen-Solal C, Roman FS, Khrestchatisky M, Rivera S, Feron F, Vignes M, PLoS One 2013 8 74667
9. Sex- and brain region-specific acceleration of beta-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. Devi L, Alldred MJ, Ginsberg SD, Ohno M, Mol Brain 2010 3 34
10. Phospho-eIF2alpha level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice. Devi L, Ohno M, PLoS One 2010 5 12974
11. Sominone improves memory impairments and increases axonal density in Alzheimer's disease model mice, 5XFAD. Joyashiki E, Matsuya Y, Tohda C, Int J Neurosci 2011 121 181 190
12. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease. Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O, Neurobiol Aging 2012 33 196 e129-140
13. Mechanisms that lessen benefits of beta-secretase reduction in a mouse model of Alzheimer's disease. Devi L, Ohno M, Transl Psychiatry 2013 3 284
14. Evidence for early cognitive impairment related to frontal cortex in the 5XFAD mouse model of Alzheimer's disease. Girard SD, Baranger K, Gauthier C, Jacquet M, Bernard A, Escoffier G, Marchetti E, Khrestchatisky M, Rivera S, Roman FS, J Alzheimers Dis 2013 33 781 796
15. Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease. Giannoni P, Gaven F, de Bundel D, Baranger K, Marchetti-Gauthier E, Roman FS, Valjent E, Marin P, Bockaert J, Rivera S, Claeysen S, Front Aging Neurosci 2013 5 96
16. PKC epsilon activation prevents synaptic loss, Abeta elevation, and cognitive deficits in Alzheimer's disease transgenic mice. Hongpaisan J, Sun MK, Alkon DL, J Neurosci 2011 31 630 643
17. Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Zhang XM, Cai Y, Xiong K, Cai H, Luo XG, Feng JC, Clough RW, Struble RG, Patrylo PR, Yan XX, Eur J Neurosci 2009 30 2271 2283
18. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Abeta and tau pathology in transgenic mouse models of Alzheimer's disease. Shao CY, Mirra SS, Sait HB, Sacktor TC, Sigurdsson EM, Acta Neuropathol 2011 122 285 292
19. Failures to reconsolidate memory in a mouse model of Alzheimer's disease. Ohno M, Neurobiol Learn Mem 2009 92 455 459
20. Onset of hippocampus-dependent memory impairments in 5XFAD transgenic mouse model of Alzheimer's disease. Girard SD, Jacquet M, Baranger K, Migliorati M, Escoffier G, Bernard A, Khrestchatisky M, Feron F, Rivera S, Roman FS, Marchetti E, Hippocampus 2014 24 762 772
21. Spine pruning in 5xFAD mice starts on basal dendrites of layer 5 pyramidal neurons. Crowe SE, Ellis-Davies GC, Brain Struct Funct 2014 219 571 580
22. Synaptic deficits in layer 5 neurons precede overt structural decay in 5xFAD mice. Buskila Y, Crowe SE, Ellis-Davies GC, Neuroscience 2013 254 152 159
23. Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation. Eimer WA, Vassar R, Mol Neurodegener 2013 8 2
24. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, Jung Y, Yau V, Searles R, Mori M, Quinn J, Hum Mol Genet 2004 13 1225 1240
25. Transcriptome differences between the frontal cortex and hippocampus of wild-type and humanized presenilin-1 transgenic mice. Unger T, Korade Z, Lazarov O, Terrano D, Schor NF, Sisodia SS, Mirnics K, Am J Geriatr Psychiatry 2005 13 1041 1051
26. Presenilin-1-dependent transcriptome changes. Mirnics K, Korade Z, Arion D, Lazarov O, Unger T, Macioce M, Sabatini M, Terrano D, Douglass KC, Schor NF, Sisodia SS, J Neurosci 2005 25 1571 1578
27. Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice. Chen SQ, Cai Q, Shen YY, Wang PJ, Teng GJ, Zhang W, Zang FC, Behav Brain Res 2012 235 1 6
28. Analysis of differential plaque depositions in the brains of Tg2576 and Tg-APPswe/PS1dE9 transgenic mouse models of Alzheimer disease. Kim TK, Lee JE, Park SK, Lee KW, Seo JS, Im JY, Kim ST, Lee JY, Kim YH, Lee JK, Han PL, Exp Mol Med 2012 44 492 502
29. Early and sustained altered expression of aging-related genes in young 3xTg-AD mice. Gatta V, D'Aurora M, Granzotto A, Stuppia L, Sensi SL, Cell death Disease 2014 5 1054
30. RNA-Seq analysis of frontal cortex and cerebellum from 5XFAD mice at early stage of disease pathology. Kim KH, Moon M, Yu SB, Mook-Jung I, Kim JI, J Alzheimers Dis 2012 29 793 808
31. Deciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer's disease by deep sequencing. Bouter Y, Kacprowski T, Weissmann R, Dietrich K, Borgers H, Brauss A, Sperling C, Wirths O, Albrecht M, Jensen LR, Kuss AW, Bayer TA, Front Aging Neurosci 2014 6 75
32. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, Michael GZ, Talafous J, Eisenberg M, Saunders AM, Roses AD, Goldaberg D, Proc Natl Acad Sci U S A 1994 91 8368 8372
33. Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). Choi SH, Leight SN, Lee VM, Li T, Wong PC, Johnson JA, Saraiva MJ, Sisodia SS, J Neurosci 2007 27 7006 7010
34. Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Li H, Wang B, Wang Z, Guo Q, Tabuchi K, Hammer RE, Sudhof TC, Zheng H, Proc Natl Acad Sci U S A 2010 107 17362 17367
35. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. Stein TD, Johnson JA, J Neurosci 2002 22 7380 7388
36. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI, Nature 1997 390 45 51
37. Suppression of aging in mice by the hormone Klotho. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M, Science 2005 309 1829 1833
38. Alpha-Klotho as a regulator of calcium homeostasis. Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, Iwano A, Obuse C, Togashi K, Tominaga M, Kita N, Tomiyama K, Iijima J, Nabeshima Y, Fujioka M, Asato R, Tanaka S, Kojima K, Ito J, Nozaki K, Hashimoto N, Ito T, Nishio T, Uchiyama T, Fujimuri T, Nabeshima Y, Science 2007 316 1615 1618
39. Differential sensitivity of murine astrocytes and neurons from different brain regions to injury. Xu L, Sapolsky RM, Giffard RG, Exp Neurol 2001 169 416 424
40. From development to dysfunction: microglia and the complement cascade in CNS homeostasis. Zabel MK, Kirsch WM, Ageing Res Rev 2013 12 749 756
41. Microglial dysfunction in brain aging and Alzheimer's disease. Mosher KI, Wyss-Coray T, Biochem Pharmacol 2014 88 594 604
42. Human CNS immune senescence and neurodegeneration. Streit WJ, Xue QS, Curr Opin Immunol 2014 29C 93 96
43. Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice. Devi L, Ohno M, Eur J Neurosci 2010 31 110 118
44. Mitochondrial dysfunction and accumulation of the beta-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. Devi L, Ohno M, Neurobiol Dis 2012 45 417 424
45. Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Terrando N, Monaco C, Ma D, Foxwell BM, Feldmann M, Maze M, Proc Natl Acad Sci U S A 2010 107 20518 20522
46. Role of interleukin-1beta in postoperative cognitive dysfunction. Cibelli M, Fidalgo AR, Terrando N, Ma D, Monaco C, Feldmann M, Takata M, Lever IJ, Nanchahal J, Fanselow MS, Maze M, Ann Neurol 2010 68 360 368
47. Does neuroinflammation fan the flame in neurodegenerative diseases? Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG, Mol Neurodegener 2009 4 47
48. Cytokines and brain injury: invited review. Kadhim HJ, Duchateau J, Sebire G, J Intensive Care Med 2008 23 236 249
49. Opposing roles for reactive astrocytes following traumatic brain injury. Laird MD, Vender JR, Dhandapani KM, Neuro-Signals 2008 16 154 164
50. Modulation of immune response by head injury. Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T, Injury 2007 38 1392 1400
51. Closed head injury-an inflammatory disease? Schmidt OI, Heyde CE, Ertel W, Stahel PF, Brain Res Brain Res Rev 2005 48 388 399
52. A CD11d monoclonal antibody treatment reduces tissue injury and improves neurological outcome after fluid percussion brain injury in rats. Bao F, Shultz SR, Hepburn JD, Omana V, Weaver LC, Cain DP, Brown A, J Neurotrauma 2012 29 2375 2392
53. Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease. Jana M, Palencia CA, Pahan K, J Immunol 2008 181 7254 7262
54. No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. Hillmann A, Hahn S, Schilling S, Hoffmann T, Demuth HU, Bulic B, Schneider-Axmann T, Bayer TA, Weggen S, Wirths O, Neurobiol Aging 2012 33 833 e839-850
55. Activation of the classical complement pathway in brain tissue of Alzheimer patients. McGeer PL, Akiyama H, Itagaki S, McGeer EG, Neurosci Lett 1989 107 341 346
56. Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease. Fonseca MI, Chu SH, Berci AM, Benoit ME, Peters DG, Kimura Y, Tenner AJ, J Neuroinflammation 2011 8 4
57. Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. Daborg J, Andreasson U, Pekna M, Lautner R, Hanse E, Minthon L, Blennow K, Hansson O, Zetterberg H, J Neural Transm 2012 119 789 797
58. Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner. Bergamaschini L, Canziani S, Bottasso B, Cugno M, Braidotti P, Agostoni A, Clin Exp Immunol 1999 115 526 533
59. Activation of complement and contact system in Alzheimer's disease. Bergamaschini L, Donarini C, Gobbo G, Parnetti L, Gallai V, Mech Ageing Dev 2001 122 1971 1983
60. Neuroprotection from complement-mediated inflammatory damage. Kulkarni AP, Kellaway LA, Lahiri DK, Kotwal GJ, Ann N Y Acad Sci 2004 1035 147 164
61. Complement activation in very early Alzheimer disease. Zanjani H, Finch CE, Kemper C, Atkinson J, McKeel D, Morris JC, Price JL, Alzheimer Dis Assoc Disord 2005 19 55 66
62. Microglia, Alzheimer's disease, and complement. Crehan H, Hardy J, Pocock J, Int J Alzheimers Dis 2012 2012 983640
63. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. Togo T, Akiyama H, Iseki E, Kondo H, Ikeda K, Kato M, Oda T, Tsuchiya K, Kosaka K, J Neuroimmunol 2002 124 83 92
64. T-cells in Alzheimer's disease. Town T, Tan J, Flavell RA, Mullan M, Neruomol Med 2005 7 255 264
65. The innate and adaptive immunological aspects in neurodegenerative diseases. Rodrigues MC, Sanberg PR, Cruz LE, Garbuzova-Davis S, J Neuroimmunol 2014 269 1 8
66. Neuroinflammation and brain functional disconnection in Alzheimer's disease. Baglio F, Saresella M, Preti MG, Cabinio M, Griffanti L, Marventano I, Piancone F, Calabrese E, Nemni R, Clerici M, Front Aging Neurosci 2013 5 81
67. What does complement do in Alzheimer's disease? Old molecules with new insights. Shen Y, Yang L, Li R, Transl Neurodegeneration 2013 2 21
68. Histological and direct evidence for the role of complement in the neuroinflammation of AD. Veerhuis R, Curr Alzheimer Res 2011 8 34 58
69. Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain. Eyles D, Almeras L, Benech P, Patatian A, Mackay-Sim A, McGrath J, Feron F, J Steroid Biochem Mol Biol 2007 103 538 545
70. Gene expression profiling in equine polysaccharide storage myopathy revealed inflammation, glycogenesis inhibition, hypoxia and mitochondrial dysfunctions. Barrey E, Mucher E, Jeansoule N, Larcher T, Guigand L, Herszberg B, Chaffaux S, Guerin G, Mata X, Benech P, Canale M, Alibert O, Maltere P, Gidrol X, BMC Vet Res 2009 5 29
71. Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. Terrier B, Joly F, Vazquez T, Benech P, Rosenzwajg M, Carpentier W, Garrido M, Ghillani-Dalbin P, Klatzmann D, Cacoub P, Saadoun D, J Immunol 2011 187 6550 6563
72. Transcriptome analysis of muscle in horses suffering from recurrent exertional rhabdomyolysis revealed energetic pathway alterations and disruption in the cytosolic calcium regulation. Barrey E, Jayr L, Mucher E, Gospodnetic S, Joly F, Benech P, Alibert O, Gidrol X, Mata X, Vaiman A, Guerin G, Anim Genet 2012 43 271 281
73. Skeletal muscle alterations and exercise performance decrease in erythropoietin-deficient mice: a comparative study. Mille-Hamard L, Billat VL, Henry E, Bonnamy B, Joly F, Benech P, Barrey E, BMC Med Genet 2012 5 29
74. Developmental vitamin D deficiency alters brain protein expression in the adult rat: implications for neuropsychiatric disorders. Almeras L, Eyles D, Benech P, Laffite D, Villard C, Patatian A, Boucraut J, Mackay-Sim A, McGrath J, Feron F, Proteomics 2007 7 769 780
75. Production of interferon-gamma by microglia. Kawanokuchi J, Mizuno T, Takeuchi H, Kato H, Wang J, Mitsuma N, Suzumura A, Mult Scler 2006 12 558 564
76. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, Das P, J Immunol 2010 184 5333 5343
77. Th17 cell-mediated neuroinflammation is involved in neurodegeneration of abeta1-42-induced Alzheimer's disease model rats. Zhang J, Ke KF, Liu Z, Qiu YH, Peng YP, PLoS One 2013 8 75786
78. The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease. Lynch MA, Immunology 2013 141 292 301
79. Abeta(1)(-)(4)(2)-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca(2)(+)-calcineurin signaling. Kook SY, Hong HS, Moon M, Ha CM, Chang S, Mook-Jung I, J Neurosci 2012 32 8845 8854
80. IFN-gamma Production by amyloid beta-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. Browne TC, McQuillan K, McManus RM, O'Reilly JA, Mills KH, Lynch MA, J Immunol 2013 190 2241 2251
81. Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases. O'Keefe GM, Nguyen VT, Benveniste EN, J Neurovirol 2002 8 496 512
82. Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer's disease. Tooyama I, Kimura H, Akiyama H, McGeer PL, Brain Res 1990 523 273 280
83. Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease. Bryan KJ, Zhu X, Harris PL, Perry G, Castellani RJ, Smith MA, Casadesus G, Mol Neurodegener 2008 3 13
84. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, Bucala R, Shachar I, J Biol Chem 2008 283 2784 2792
85. CD74 interacts with APP and suppresses the production of Abeta. Matsuda S, Matsuda Y, D'Adamio L, Mol Neurodegener 2009 4 41
86. Human IRGM gene "to be or not to be" Bekpen C, Xavier RJ, Eichler EE, Semin Immunopathol 2010 32 437 444
87. p47 GTPases: regulators of immunity to intracellular pathogens. Taylor GA, Feng CG, Sher A, Nat Rev Immunol 2004 4 100 109
88. Immune-related GTPase M (IRGM1) regulates neuronal autophagy in a mouse model of stroke. He S, Wang C, Dong H, Xia F, Zhou H, Jiang X, Pei C, Ren H, Li H, Li R, Xu H, Autophagy 2012 8 1621 1627
89. Immune-related GTPase Irgm1 exacerbates experimental auto-immune encephalomyelitis by promoting the disruption of blood-brain barrier and blood-cerebrospinal fluid barrier. Wang C, Wang C, Dong H, Wu XM, Wang C, Xia F, Li G, Jia X, He S, Jiang X, Li H, Xu H, Mol Immunol 2013 53 43 51
90. The p47 GTPase Lrg-47 (Irgm1) links host defense and hematopoietic stem cell proliferation. Feng CG, Weksberg DC, Taylor GA, Sher A, Goodell MA, Cell Stem Cell 2008 2 83 89
91. Disruption of the Toxoplasma gondii parasitophorous vacuole by IFNgamma-inducible immunity-related GTPases (IRG proteins) triggers necrotic cell death. Zhao YO, Khaminets A, Hunn JP, Howard JC, PLoS Pathog 2009 5 1000288
92. Genetic deficiency of Irgm1 (LRG-47) suppresses induction of experimental autoimmune encephalomyelitis by promoting apoptosis of activated CD4+ T cells. Xu H, Wu ZY, Fang F, Guo L, Chen D, Chen JX, Stern D, Taylor GA, Jiang H, Yan SS, FASEB J 2010 24 1583 1592
93. Balance of Irgm protein activities determines IFN-gamma-induced host defense. Henry SC, Daniell XG, Burroughs AR, Indaram M, Howell DN, Coers J, Starnbach MN, Hunn JP, Howard JC, Feng CG, Sher A, Taylor GA, J Leukoc Biol 2009 85 877 885
94. The mouse resistance protein Irgm1 (LRG-47): a regulator or an effector of pathogen defense? Hunn JP, Howard JC, PLoS Pathog 2010 6 1001008
95. A gene network regulating lysosomal biogenesis and function. Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, Di Malta C, Donaudy F, Embrione V, Polishchuk RS, Banfi S, Parenti G, Cattaneo E, Ballabio A, Science 2009 325 473 477
96. TFEB links autophagy to lysosomal biogenesis. Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, Erdin SU, Huynh T, Medina D, Colella P, Sardiello M, Rubinsztein DC, Ballabio A, Science 2011 332 1429 1433
97. A role for presenilins in autophagy revisited: normal acidification of lysosomes in cells lacking PSEN1 and PSEN2. Zhang X, Garbett K, Veeraraghavalu K, Wilburn B, Gilmore R, Mirnics K, Sisodia SS, J Neurosci 2012 32 8633 8648
98. The up-regulation of endosomal-lysosomal components in amyloid beta-resistant cells. Li Y, Xu C, Schubert D, J Neurochem 1999 73 1477 1482
99. The role of the endosomal/lysosomal system in amyloid-beta production and the pathophysiology of Alzheimer's disease: reexamining the spatial paradox from a lysosomal perspective. Pasternak SH, Callahan JW, Mahuran DJ, J Alzheimers Dis 2004 6 53 65
100. The Alzheimer's beta-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Kandalepas PC, Sadleir KR, Eimer WA, Zhao J, Nicholson DA, Vassar R, Acta Neuropathol 2013 126 329 352
101. Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H, J Biol Chem 2013 288 1295 1306
102. The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review. Nixon RA, Cataldo AM, Mathews PM, Neurochem Res 2000 25 1161 1172
103. Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Gobin SJ, Peijnenburg A, Keijsers V, van den Elsen PJ, Immunity 1997 6 601 611
104. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Muhlethaler-Mottet A, Di Berardino W, Otten LA, Mach B, Immunity 1998 8 157 166
105. An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Driggers PH, Ennist DL, Gleason SL, Mak WH, Marks MS, Levi BZ, Flanagan JR, Appella E, Ozato K, Proc Natl Acad Sci U S A 1990 87 3743 3747
106. IFN consensus sequence binding protein (ICSBP) is a conditional repressor of IFN inducible promoters. Weisz A, Kirchhoff S, Levi BZ, Int Immunol 1994 6 1125 1131
107. Two cis-DNA elements involved in myeloid-cell-specific expression and gamma interferon (IFN-gamma) activation of the human high-affinity Fc gamma receptor gene: a novel IFN regulatory mechanism. Perez C, Wietzerbin J, Benech PD, Mol Cell Biol 1993 13 2182 2192
108. IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype. Masuda T, Tsuda M, Yoshinaga R, Tozaki-Saitoh H, Ozato K, Tamura T, Inoue K, Cell Reports 2012 1 334 340
109. The IRF family transcription factors in immunity and oncogenesis. Tamura T, Yanai H, Savitsky D, Taniguchi T, Annu Rev Immunol 2008 26 535 584
110. IRF8 regulates myeloid and B lymphoid lineage diversification. Wang H, Morse HC 3rd, Immunol Res 2009 43 109 117
111. Interferon regulatory factor 8 regulates pathways for antigen presentation in myeloid cells and during tuberculosis. Marquis JF, Kapoustina O, Langlais D, Ruddy R, Dufour CR, Kim BH, MacMicking JD, Giguere V, Gros P, PLoS Genet 2011 7 1002097
112. Irf8-regulated genomic responses drive pathological inflammation during cerebral malaria. Berghout J, Langlais D, Radovanovic I, Tam M, MacMicking JD, Stevenson MM, Gros P, PLoS Pathog 2013 9 1003491
113. Transforming growth factor beta1 up-regulates interferon regulatory factor 8 during dendritic cell development. Ju XS, Ruau D, Jantti P, Sere K, Becker C, Wiercinska E, Bartz C, Erdmann B, Dooley S, Zenke M, Eur J Immunol 2007 37 1174 1183
114. Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro. Suzumura A, Sawada M, Yamamoto H, Marunouchi T, J Immunol 1993 151 2150 2158
115. Antigen presentation in the central nervous system. The inhibitory effect of IL-10 on MHC class II expression and production of cytokines depends on the inducing signals and the type of cell analyzed. Frei K, Lins H, Schwerdel C, Fontana A, J Immunol 1994 152 2720 2728
116. NADPH oxidase and reactive oxygen species contribute to alcohol-induced microglial activation and neurodegeneration. Qin L, Crews FT, J Neuroinflammation 2012 9 5
117. NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Qin L, Liu Y, Hong JS, Crews FT, Glia 2013 61 855 868
118. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM, J Neurosci 2001 21 4183 4187
119. Mitochondrial alterations near amyloid plaques in an Alzheimer's disease mouse model. Xie H, Guan J, Borrelli LA, Xu J, Serrano-Pozo A, Bacskai BJ, J Neurosci 2013 33 17042 17051
120. Quantitative proteomic analysis of the hippocampus in the 5XFAD mouse model at early stages of Alzheimer's disease pathology. Hong I, Kang T, Yoo Y, Park R, Lee J, Lee S, Kim J, Song B, Kim SY, Moon M, Yun KN, Kim JY, Mook-Jung I, Park YM, Choi S, J Alzheimers Dis 2013 36 321 334
121. The use of interferon-gamma therapy in chronic granulomatous disease. Errante PR, Frazao JB, Condino-Neto A, Recent Patents Anti-infective drug Dis 2008 3 225 230
122. Jak/STAT signaling pathway regulates nox1 and nox4-based NADPH oxidase in human aortic smooth muscle cells. Manea A, Tanase LI, Raicu M, Simionescu M, Arterioscler Thromb Vasc Biol 2010 30 105 112
123. In vitro activation of mouse neutrophils by recombinant human interferon-gamma: increased phagocytosis and release of reactive oxygen species and pro-inflammatory cytokines. Marchi LF, Sesti-Costa R, Ignacchiti MD, Chedraoui-Silva S, Mantovani B, Int Immunopharmacol 2014 18 228 235
124. p40phox: the last NADPH oxidase subunit. Matute JD, Arias AA, Dinauer MC, Patino PJ, Blood Cells Mol Dis 2005 35 291 302
125. Fc gamma R-stimulated activation of the NADPH oxidase: phosphoinositide-binding protein p40phox regulates NADPH oxidase activity after enzyme assembly on the phagosome. Tian W, Li XJ, Stull ND, Ming W, Suh CI, Bissonnette SA, Yaffe MB, Grinstein S, Atkinson SJ, Dinauer MC, Blood 2008 112 3867 3877
126. Vav proteins in neutrophils are required for FcgammaR-mediated signaling to Rac GTPases and nicotinamide adenine dinucleotide phosphate oxidase component p40(phox). Utomo A, Cullere X, Glogauer M, Swat W, Mayadas TN, J Immunol 2006 177 6388 6397
127. Activation of NADPH oxidase in Alzheimer's disease brains. Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, Hayakawa T, Nunomura A, Chiba S, Perry G, Smith MA, Fujimoto S, Biochem Biophys Res Commun 2000 273 5 9
128. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. Abramov AY, Canevari L, Duchen MR, J Neurosci 2004 24 565 575
129. CD40 expression by microglial cells is required for their completion of a two-step activation process during central nervous system autoimmune inflammation. Ponomarev ED, Shriver LP, Dittel BN, J Immunol 2006 176 1402 1410
130. Expression of immunohistochemical markers on microglia in Creutzfeldt-Jakob disease and Alzheimer's disease: morphometric study and review of the literature. Wojtera M, Sobow T, Kloszewska I, Liberski PP, Brown DR, Sikorska B, Folia Neuropathol 2012 50 74 84
131. Acute and chronic stress-induced disturbances of microglial plasticity, phenotype and function. Walker FR, Nilsson M, Jones K, Curr Drug Targets 2013 14 1262 1276
132. Identification of Fc gamma RI, II and III on normal human brain ramified microglia and on microglia in senile plaques in Alzheimer's disease. Peress NS, Fleit HB, Perillo E, Kuljis R, Pezzullo C, J Neuroimmunol 1993 48 71 79
133. The Rac target NADPH oxidase p67phox interacts preferentially with Rac2 rather than Rac1. Dorseuil O, Reibel L, Bokoch GM, Camonis J, Gacon G, J Biol Chem 1996 271 83 88
134. Inhibition of superoxide production in B lymphocytes by rac antisense oligonucleotides. Dorseuil O, Vazquez A, Lang P, Bertoglio J, Gacon G, Leca G, J Biol Chem 1992 267 20540 20542
135. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Rogers J, Lue LF, Neurochem Int 2001 39 333 340
136. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, Lossinsky AS, Graves MC, Gustavson A, Sayre J, Sofroni E, Suarez T, Chiapelli F, Bernard G, J Alzheimers Dis 2005 7 221 232 discussion 255-262
137. Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. Koenigsknecht J, Landreth G, J Neurosci 2004 24 9838 9846
138. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, Heine H, Penke B, Neumann H, Fassbender K, Brain 2005 128 1778 1789
139. Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. Luo J, Elwood F, Britschgi M, Villeda S, Zhang H, Ding Z, Zhu L, Alabsi H, Getachew R, Narasimhan R, Wabl R, Fainberg N, James ML, Wong G, Relton J, Gambhir SS, Pollard JW, Wyss-Coray T, J Exp Med 2013 210 157 172
140. Variant TREM2 as risk factor for Alzheimer's disease. Neumann H, Daly MJ, N Engl J Med 2013 368 182 184
141. TREM2 variants in Alzheimer's disease. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Lupton MK, Ryten M, Brown K, Lowe J, Ridge PG, Hammer MB, Wakutani Y, Hazrati L, Proitsi P, Newhouse S, Lohmann E, Erginel-Unaltuna N, Medway C, Hanagasi H, Troakes C, Gurvit H, Bilgic B, Al-Sarraj S, Benitez B, Cooper B, Carrell D, et al. N Engl J Med 2013 368 117 127
142. Variant of TREM2 associated with the risk of Alzheimer's disease. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K, N Engl J Med 2013 368 107 116
143. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H, PLoS Med 2007 4 124
144. Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Piccio L, Buonsanti C, Mariani M, Cella M, Gilfillan S, Cross AH, Colonna M, Panina-Bordignon P, Eur J Immunol 2007 37 1290 1301
145. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I, Deller T, Glia 2008 56 1438 1447
146. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Hamerman JA, Tchao NK, Lowell CA, Lanier LL, Nat Immunol 2005 6 579 586
147. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL, J Immunol 2006 177 2051 2055
148. Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. Vardy ER, Rice PJ, Bowie PC, Holmes JD, Grant PJ, Hooper NM, J Alzheimers Dis 2007 12 285 290
149. The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Freude S, Schilbach K, Schubert M, Curr Alzheimer Res 2009 6 213 223
150. IGF-1 can either protect against or increase LPS-induced damage in the developing rat brain. Pang Y, Zheng B, Campbell LR, Fan LW, Cai Z, Rhodes PG, Pediatr Res 2010 67 579 584
151. Phosphatidylinositol 3-kinase-mediated regulation of neuronal apoptosis and necrosis by insulin and IGF-I. Ryu BR, Ko HW, Jou I, Noh JS, Gwag BJ, J Neurobiol 1999 39 536 546
152. Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling. Davila D, Torres-Aleman I, Mol Biol Cell 2008 19 2014 2025
153. Astrocyte-Specific Overexpression of Insulin-Like Growth Factor-1 Protects Hippocampal Neurons and Reduces Behavioral Deficits following Traumatic Brain Injury in Mice. Madathil SK, Carlson SW, Brelsfoard JM, Ye P, D'Ercole AJ, Saatman KE, PLoS One 2013 8 67204
154. Prostaglandin E2 is a novel inducer of oncostatin-M expression in macrophages and microglia. Repovic P, Benveniste EN, J Neurosci 2002 22 5334 5343
155. Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo. Weiss TW, Samson AL, Niego B, Daniel PB, Medcalf RL, FASEB J 2006 20 2369 2371
156. Prostaglandin E(2) induces oncostatin M expression in human chronic wound macrophages through Axl receptor tyrosine kinase pathway. Ganesh K, Das A, Dickerson R, Khanna S, Parinandi NL, Gordillo GM, Sen CK, Roy S, J Immunol 2012 189 2563 2573
157. Protective role of STAT3 in NMDA and glutamate-induced neuronal death: negative regulatory effect of SOCS3. Park KW, Nozell SE, Benveniste EN, PLoS One 2012 7 50874
158. Role of progranulin as a biomarker for Alzheimer's disease. Sleegers K, Brouwers N, Van Broeckhoven C, Biomark Med 2010 4 37 50
159. Progranulin is a chemoattractant for microglia and stimulates their endocytic activity. Pickford F, Marcus J, Camargo LM, Xiao Q, Graham D, Mo JR, Burkhardt M, Kulkarni V, Crispino J, Hering H, Hutton M, Am J Pathol 2011 178 284 295
160. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, Syed NM, Lai Y, Lin EA, Kong L, Su J, Yin F, Ding AH, Zanin-Zhorov A, Dustin ML, Tao J, Craft J, Yin Z, Feng JQ, Abramson SB, Yu XP, Liu CJ, Science 2011 332 478 484
161. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L, Erdjument-Bromage H, Tempst P, Wright CD, Ding A, Cell 2002 111 867 878
162. HDL/apolipoprotein A-I binds to macrophage-derived progranulin and suppresses its conversion into proinflammatory granulins. Okura H, Yamashita S, Ohama T, Saga A, Yamamoto-Kakuta A, Hamada Y, Sougawa N, Ohyama R, Sawa Y, Matsuyama A, J Atheroscler Thromb 2010 17 568 577
163. Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease. Bhattacharya S, Haertel C, Maelicke A, Montag D, PLoS One 2014 9 89454
164. ArrayExpress database. [ http://www.ebi.ac.uk/arrayexpress ]
165. Ingenuity Systems. [ http://www.ingenuity.com ]
166. Prediguard. [ http://www.laboratoire-genex.fr ]